Dr. Vaishampayan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4100 John R St
Gershenson Radiation Oncology CTR
Detroit, MI 48201Phone+1 800-527-6266Fax+1 313-576-9640
Summary
- Dr. Nitin Vaishampayan is a radiation oncologist based in Detroit, MI with a notable teaching role at Karmanos Cancer Center. His medical education started at University of Michigan, followed by an internship and residencies at Wayne State University School of Medicine and Detroit Medical Center/Wayne State University respectively. Having specialized in Radiation Oncology, he has made substantial contributions to medical literature, with numerous well-cited publications in recognized journals on topics ranging from Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer, pediatric myeloid sarcoma to the prognostic value of ratio changes in cervical cancer patients.
Education & Training
Detroit Medical Center/Wayne State UniversityResidency, Radiation Oncology, 1992 - 1996
Wayne State University School of MedicineInternship, Transitional Year, 1991 - 1992
University of Michigan Medical SchoolClass of 1991
Certifications & Licensure
MI State Medical License 1996 - 2027- American Board of Radiology Radiation Oncology
Publications & Presentations
PubMed
- 127 citationsCognitive impairment in musculoskeletal pain patientsDonald G. Kewman, Nitin Vaishampayan, David H. Zald, Bum Han
International Journal of Psychiatry in Medicine. 1991-09-01 - 26 citationsPrognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervic...Hamilton Trinh, Stephen P. Dzul, Jalal Hyder, Hyejeong Jang, Seongho Kim
Clinica Chimica Acta; International Journal of Clinical Chemistry. 2020-11-01 - 1 citationsPhase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible Patients.Ulka N Vaishampayan, Lance Heilbrun, Nitin Vaishampayan, Felicity W K Harper, Dongping Shi
International Journal of Radiation Oncology, Biology, Physics. 2024-04-01
Press Mentions
Post-ASCO News Alert: Novartis’ Lu-PSMA Early Uptake in Castration-Resistant Prostate Cancer May Be Stalled by Radiopharmaceutical Logistic Issues, Though ApprovableJune 25th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
